NCT00074191 (Protocol-A) is a Phase 2 clinical trial of cytarabine in Lymphoma, sponsored by OHSU Knight Cancer Institute.

Who is sponsoring NCT00074191?

NCT00074191 is sponsored by OHSU Knight Cancer Institute.

What drugs are being tested in NCT00074191?

Interventions in NCT00074191: cytarabine, dexamethasone, lomustine, methotrexate, procarbazine hydrochloride.

Is NCT00074191 still recruiting?

NCT00074191 is currently completed. Last updated 19 April 2017.

Last reviewed 2017-04-19 · How we verify

NCT00074191: Protocol-A

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Combination Chemotherapy (Methotrexate, Procarbazine And CCNU), Intraventricular Cytarabine And Methotrexate, +/- Intra-Ocular Chemotherapy For Patients With Primary Central Nervous System Lymphoma

Completed Phase 2 Last updated 19 April 2017

What this trial tests

Phase 2 trial testing cytarabine in Lymphoma in 1 participant. Completed in 1 October 2000.

Timeline

1 January 2000

Primary endpoint
1 October 2000

1 October 2000

Quick facts

Lead sponsor	OHSU Knight Cancer Institute
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Masking	none
Primary purpose	treatment
Enrollment	1
Start date	1 January 2000
Primary completion	1 October 2000
Estimated completion	1 October 2000
Sites	1 location across United States

Drugs / interventions tested

cytarabine — full drug profile →
dexamethasone (dexamethasone) — full drug profile →
lomustine (LOMUSTINE) — full drug profile →
methotrexate — full drug profile →
procarbazine hydrochloride

Conditions studied

Lymphoma — all drugs for Lymphoma →

Sponsor

OHSU Knight Cancer Institute

Who can join

Adults 16 to 75, any sex, with Lymphoma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Survival as measured by clinical and radiographic response at 5 years following completion of study treatment
Time frame: 5 years

Sponsor's own description

RATIONALE: Drugs used in chemotherapy, such as methotrexate, procarbazine, lomustine, dexamethasone, and cytarabine, use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have primary CNS lymphoma.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of cytarabine

Trials testing the same drug.

NCT07441967 — The Safety and Efficacy of the Regimen of Thiotepa + Fludarabine +Granulocyte Colony-Stimulating Factor+ Cytarabine + Bu · Phase 2 · not yet recruiting
NCT06744556 — HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML · Phase 2 · recruiting
NCT06744504 — Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1 · Phase 3 · recruiting
NCT06451861 — Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML · Phase 2 · recruiting
NCT05712278 — A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid L · Phase 1 · terminated

Other recruiting trials for Lymphoma

Currently open trials in the same condition.

NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT06856226 — Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing · recruiting
NCT07226934 — An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers · NA · recruiting
NCT07138547 — GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma · Phase 1, PHASE2 · recruiting

Other OHSU Knight Cancer Institute trials

Trials by the same sponsor.

NCT05453851 — A Surgical Procedure (Total Pancreatectomy) With a Transplant Procedure (Islet Cell Autotransplantation) for the Treatme · Phase 1, PHASE2 · not yet recruiting
NCT07511504 — Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanc · Phase 2 · not yet recruiting
NCT07434128 — Mammogram Pretreatment With Ulipristal Acetate · Phase 2 · not yet recruiting
NCT07504835 — GET FIT Together: Testing a Socially Enhanced Exercise Program in Older Men With Prostate Cancer · NA · not yet recruiting
NCT07498517 — Safety and Efficacy of a Single Dose of Gruticibart to Prevent CRT · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00074191 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by OHSU Knight Cancer Institute
Last refreshed: 19 April 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00074191.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing